VX-765 prevents intestinal ischemia-reperfusion injury by inhibiting NLRP3 inflammasome

Heping Lyu,Haizhen Ni,Jingyong Huang,Guanfeng Yu,Zhongjing Zhang,Qiyu Zhang

DOI: https://doi.org/10.1016/j.tice.2021.101718

2022-01-01

Abstract:Background: Intestinal ischemia-reperfusion injury (IIRI) is a common clinical event that can cause serious consequences. The study aimed to investigated the effect of VX-765 in IIRI and its mechanism. Methods: The hypoxia-reoxygenation (H/R) cell model and IIRI mouse model were generated to examine the in vitro and in vivo effects of VX-765 on IIRI. IIRI was evaluated by histological assessment. ELISA was performed to determine the levels of IL-6, TNF-alpha, IL-1 beta, caspase-1, and GSDMD in intestinal tissues as well as the levels of MDA, SOD, CAT, caspase-1, and GSDMD in Caco-2 cells. Relative protein levels of NLRP3, ASC, IL-18, IL-1 beta, cleaved Caspasel, and GSDMD-N were analyzed by Western blotting. CCK-8 Assay was conducted to determine the optimal concentration of VX-765 for the in vitro studies. Flow cytometry, fluorescence microscopy and real time PCR (RT-PCR) were used to assess ROS levels and the mRNA levels of IL-18 and IL-1 beta, respectively. Immunofluorescence staining was performed to examine the subcellular localization of P65 and NLRP3. Results: VX-765 reduced IIRI-induced oxidative stress and inflammatory response both in vivo and in vitro, while it decreased the levels of TNF-alpha, IL-6, IL-1 beta as well as the modified Park/Chiu scores. The optimal concentration of VX-765 for the in vitro studies was 10 mu M. Moreover, VX-765 inhibited the nuclear translocation of P65, reduced oxidative stress and down-regulated the activation of NLRP3 inflammasome. Conclusion: VX-765 prevents IIRI presumably by inhibiting the activation of NLRP3 inflammasome.